Aldebaran Financial Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the first quarter, Holdings Channel reports. The fund owned 5,100 shares of the company’s stock after selling 50 shares during the period. Aldebaran Financial Inc.’s holdings in Eli Lilly and were worth $429,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Private Trust Co. NA boosted its stake in Eli Lilly and by 43.5% in the first quarter. Private Trust Co. NA now owns 7,787 shares of the company’s stock valued at $654,000 after buying an additional 2,360 shares during the last quarter. Alpha Windward LLC boosted its stake in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the last quarter. Prospera Financial Services Inc boosted its stake in Eli Lilly and by 6.7% in the first quarter. Prospera Financial Services Inc now owns 14,258 shares of the company’s stock valued at $1,208,000 after buying an additional 895 shares during the last quarter. First Command Financial Services Inc. boosted its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Finally, Parametrica Management Ltd bought a new stake in Eli Lilly and during the first quarter valued at $242,000. Institutional investors and hedge funds own 75.59% of the company’s stock.
Eli Lilly and Company (LLY) traded down 0.456% during mid-day trading on Friday, hitting $77.445. 1,549,866 shares of the stock traded hands. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The firm has a market cap of $81.70 billion, a P/E ratio of 33.511 and a beta of 0.34. The firm’s 50-day moving average price is $82.55 and its 200-day moving average price is $81.88.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm posted $0.86 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.67%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/18/aldebaran-financial-inc-lowers-position-in-eli-lilly-and-company-lly.html.
LLY has been the subject of several research reports. BMO Capital Markets set a $71.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, April 25th. Argus cut shares of Eli Lilly and from a “buy” rating to a “hold” rating and increased their target price for the company from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $92.00 target price on shares of Eli Lilly and in a research note on Tuesday, May 16th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research note on Sunday, May 21st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $88.27.
In other news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the sale, the insider now directly owns 124,475,804 shares of the company’s stock, valued at approximately $10,337,715,522.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is currently owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.